Tag: VenaSeal
Manj Gohel
“As I learned more about venous pathologies, it became abundantly clear that patients with venous disease were a largely neglected population in need of...
Five-year, single-centre VenaSeal outcomes for symptomatic saphenous incompetence revealed
Morwan Bahi (Wellington Regional Hospital, Wellington, New Zealand) presented five-year results of a retrospective, observational, single-centre study detailing outcomes for all patients with symptomatic...
VenaSeal superior for management of chronic venous insufficiency, finds systematic review
According to a network meta-analysis, the VenaSeal system (Medtronic) is “a promising therapeutic option for anatomic success at six months”. This study, published in...
Medtronic receives favourable CMS ruling on VenaSeal
The US Centers for Medicare and Medicaid Services (CMS) has posted the 2018 Medicare Physician Fee Schedule (CMS-1678-F) and Hospital Outpatient Prospective Payment and...
Adhesive closure “an effective add-on” to thermal ablation
Endovenous adhesive closure systems are a useful adjunct to thermal ablation treatment for varicose veins, but it is vital that the possible side-effects of...
Medtronic VenaSeal closure system demonstrates clinical and quality of life benefits
Three-year outcomes from the VeClose US pivotal clinical trial and one-year data from the WAVES study have been presented at the 2017 CX Symposium...
VeClose trial reports “excellent” clinical and quality of life outcomes at...
The pivotal VeClose trial is investigating the performance of the VenaSeal cyanoacrylate-based adhesive (Medtronic) for vein closure. At LINC 2017, Vascular News caught up...
VeClose trial indicates 24-month non-inferiority of VenaSeal versus radiofrequency ablation
Two-year outcomes of the VeClose pivotal trial have been reported, showing a 94.3% closure rate and “continued non-inferiority results to radiofrequency ablation” when using...
WAVES trial shows 100% vein closure at one month with short...
A post-market evaluation of the VenaSeal closure system (Medtronic) has found that, at one month, 100% of treated veins remained closed, quality of life...